SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITD-mutant AML.
Saved in:
| Title: | SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITD-mutant AML. |
|---|---|
| Authors: | Pacharne S; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Wellcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Dovey OM; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom., Cooper JL; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom., Gu M; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Wellcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Friedrich MJ; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Department of Medicine II, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany., Rajan SS; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; United Kingdom Dementia Research Institute, University of Cambridge, Cambridge, United Kingdom., Barenboim M; Department of Pediatrics and Children's Cancer Research Center, Klinikum Rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany., Collord G; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Wellcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Vijayabaskar MS; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Wellcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Ponstingl H; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom., De Braekeleer E; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Wellcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Bautista R; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom., Mazan M; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Research and Development Department, Selvita S.A., Krakow, Poland., Rad R; Department of Medicine II, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; and., Tzelepis K; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Gurdon Institute.; Department of Pathology, and., Wright P; Department of Pathology, and., Gozdecka M; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Wellcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Vassiliou GS; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Wellcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, Cambridge University Hospitals National Health Service (NHS) Trust, Cambridge, United Kingdom. |
| Source: | Blood advances [Blood Adv] 2021 May 11; Vol. 5 (9), pp. 2412-2425. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
